Pharmaqo US – GW501516 (Cardarine): Uses, Effects, Side Effects, and Safety Guide

Pharmaqo US – GW501516 (Cardarine)

Pharmaqo US – GW501516 (Cardarine) is marketed as an oral product containing GW501516, also known as Cardarine or Endurobol. Unlike anabolic steroids or SARMs, GW501516 is a PPAR-δ (Peroxisome Proliferator-Activated Receptor Delta) agonist that was originally investigated for potential applications in metabolic and cardiovascular diseases.

General product information:

• Product Name: Pharmaqo US – GW501516
• Active Ingredient: GW501516 (Cardarine)
• Common Names: Cardarine, Endurobol, GW-501516
• Dosage Form: Oral capsules or tablets (depending on product presentation)
• Drug Class: PPAR-δ receptor agonist (research compound)

GW501516 is not an approved medicine for human use. Clinical development was discontinued after animal studies identified significant safety concerns, including an increased incidence of cancer at experimental doses.

What Is Pharmaqo US – GW501516?

Pharmaqo US – GW501516 is marketed as an oral product containing the research compound GW501516.

General product details:

• Compound: GW501516
• Common Name: Cardarine
• Alternative Name: Endurobol
• Administration: Oral

Although frequently grouped with SARMs in fitness discussions, Cardarine is not a SARM. Instead, it activates the PPAR-δ receptor, which plays an important role in energy metabolism and fatty acid oxidation.

What Is GW501516 (Cardarine)?

GW501516 is a synthetic compound developed during the 1990s as a potential treatment for:

• Dyslipidemia
• Obesity
• Metabolic disorders
• Cardiovascular disease

Rather than acting on androgen receptors, GW501516 targets PPAR-δ receptors, influencing how the body utilizes fats and energy.

How Does GW501516 Work?

GW501516 activates PPAR-δ receptors, which regulate genes involved in energy metabolism.

Activation of these receptors may influence:

• Fatty acid oxidation
• Skeletal muscle metabolism
• Glucose utilization
• Energy production
• Endurance-related metabolic pathways

Unlike anabolic steroids, GW501516 does not directly increase testosterone or stimulate androgen receptors.

Medical Background

GW501516 was investigated as a possible treatment for metabolic diseases because early research suggested potential benefits for lipid metabolism and insulin sensitivity.

However, human development was halted after long-term animal studies demonstrated an increased occurrence of cancers in multiple organs, preventing its approval for therapeutic use.

Cardarine in Fitness and Bodybuilding Discussions

Within fitness communities, Cardarine is commonly discussed because of associations with:

• Improved endurance
• Increased exercise capacity
• Fat metabolism
• Conditioning during cardiovascular training

These uses are not approved medical indications, and the compound remains prohibited in competitive sport by anti-doping organizations.

Potential Safety Concerns

Although human safety data are limited, reported and theoretical concerns include:

• Headaches
• Muscle discomfort
• Stomach pain
• Changes in metabolism
• Unknown long-term health effects

The most significant concern is that preclinical animal studies found increased cancer development, leading researchers to discontinue clinical development. Whether these findings translate directly to humans remains uncertain, but they are considered a major safety concern.

Cardiovascular and Metabolic Effects

Research has explored GW501516 for potential effects on:

• Lipid metabolism
• Fat oxidation
• Exercise metabolism
• Insulin sensitivity

Because development was discontinued, these potential therapeutic applications were never established for routine clinical use.

Product Quality Considerations

Products marketed as GW501516 outside regulated pharmaceutical systems may vary in:

• Active ingredient identity
• Concentration
• Purity
• Manufacturing standards
• Batch consistency

Potential concerns include:

• Counterfeit products
• Contamination
• Incorrect labeling
• Inconsistent potency

Independent laboratory verification may help assess product identity where available.

Storage Recommendations

Store the product:

• At room temperature
• Away from moisture
• Away from direct sunlight
• In its original packaging
• Out of reach of children

Do not use products with damaged packaging or past their expiry date.

Frequently Asked Questions

What is Pharmaqo US – GW501516?

It is marketed as an oral product containing GW501516 (Cardarine), a research compound that acts as a PPAR-δ agonist.

Is Cardarine a SARM?

No. Although it is often grouped with SARMs online, Cardarine is not a Selective Androgen Receptor Modulator (SARM). It is a PPAR-δ receptor agonist.

Is GW501516 approved as a medicine?

No. GW501516 has not been approved for therapeutic use in humans, and its clinical development was discontinued because of significant safety concerns identified in animal studies.

Does Cardarine increase testosterone?

No. GW501516 does not act on testosterone or androgen receptors and is not an anabolic steroid.

Is GW501516 a dietary supplement?

No. GW501516 is a synthetic research compound and is not an approved dietary supplement or prescription medicine.

Final Thoughts

Pharmaqo US – GW501516 (Cardarine) is marketed as a PPAR-δ receptor agonist rather than an anabolic steroid or SARM. It was originally investigated for potential metabolic and cardiovascular applications but was never approved for human therapeutic use because of serious safety concerns observed during preclinical research. Anyone considering products containing GW501516 should understand its experimental status, lack of regulatory approval, and the importance of product quality and safety.

Disclaimer: This article is provided for educational and informational purposes only. It is not medical advice and should not replace consultation with a qualified healthcare professional.